ValiRx plc

Equities

VAL

GB00BLH13C52

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:06 2024-04-29 am EDT			5-day change	1st Jan Change
3.35 ^GBX	0.00%		-2.90%	-43.22%

Apr. 22	Valirx plc Announces Directorate Changes	CI
Mar. 21	ValiRx inks evaluation deal with Imperial College London for research	AN

ValiRx says requisition notice from shareholder group is invalid

February 13, 2024 at 09:46 am EST

(Alliance News) - ValiRx PLC on Tuesday said a requisition notice, which it received earlier in February, has been confirmed as invalid following legal advice.

ValiRx is a Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics. Its shares were down 2.1% to 4.65 pence each in London on Tuesday afternoon.

Earlier in February, it had said that it has received a requisition notice from a shareholder group proposing certain changes to the board. At the time, it said it will be seeking legal advice on the validity of the requisition notice.

On Tuesday, ValiRx said the notice has been confirmed as invalid.

"The requisitioning shareholders have been informed and shareholders are advised to take no action at this time," ValiRx said.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Latest news about ValiRx plc

Valirx plc Announces Directorate Changes	Apr. 22	CI
ValiRx inks evaluation deal with Imperial College London for research	Mar. 21	AN
ValiRx plc Announces Signature of an Evaluation Agreement with Imperial College London	Mar. 21	CI
EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat	Mar. 19	AN
ValiRx Kick off Search for New CEO	Mar. 19	MT
Valirx plc Announces Board Appointments, Subject to Completion of Regulatory Due Diligence	Mar. 19	CI
EARNINGS: Leeds awaiting Hemmers sale, Macfarlane ups full-year payout	Feb. 29	AN
Valirx plc Intends to Appoint Martin Gouldstone as Non-Executive Director	Feb. 29	CI
ValiRx Says Shareholder Group's Requisition Notice Invalid	Feb. 13	MT
ValiRx says requisition notice from shareholder group is invalid	Feb. 13	AN
ValiRx signs research sharing deal with Dundee University	Feb. 12	AN
Valirx Signs Research, Evaluation Agreements with University of Dundee	Feb. 12	MT
ValiRx plc Announces Agreement with Dundee Uni and Project Initiation	Feb. 12	CI
ValiRx receives shareholder request for board change	Feb. 09	AN
ValiRx plc Announces Resignation of Stella Panu as A Non-Executive Director, Effective from 15 April 2024	Jan. 18	CI
ValiRx raises GBP192,200, part of wider GBP1.8 million raise	Dec. 19	AN
Good Energy says ZapMap expands into mainland Europe	Dec. 13	AN
ValiRx Signs Licensing Option Deal with Ambrose Healthcare	Dec. 05	MT
ValiRx says ValiSeek inks deal to licence VAL401 drug with Ambrose	Dec. 05	AN
AIM WINNERS & LOSERS: tinyBuild warns on revenue; ValiRx rises	Dec. 05	AN
ValiRx signs deal to evaluate StingRay Bio drug candidates	Nov. 10	AN
ValiRX, StingRay Bio Sign Evaluation Agreement for Oncology Drug Candidates	Nov. 10	MT
ValiRx plc Enters into an Agreement with StingRay Bio Limited to Investigate a Lead Series of Drug Candidates for Use in Oncology	Nov. 10	CI
ValiRx sees no reason for shares jump; notes TheoremRx mulls merger	23-10-06	AN
FTSE 100 Finishes Higher Despite Fading Nvidia Buzz	23-08-24	DJ

Chart ValiRx plc

Duration

Period

More charts

Company Profile

ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.

Sector

Biotechnology & Medical Research

Calendar

2024-09-24 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VALIRX PLC	-43.22%	5.52M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs